Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Phase I

This is a first-in-human, open-label, non-randomized, 4-part Phase 1 trial to determine the safety profile and identify the maximum tolerated dose (MTD) and / or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda).
Phase I
I
Davis, Elizabeth
NCT04198766
VICCPHI2135

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

Head/Neck

A Phase 2 Study of Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma.
Head/Neck
II
Gibson, Mike
NCT04675294
VICCHN20127

Radiation Therapy and Pembrolizumab or Cisplatin in Treating Patients with Stage III / IV p16 Positive Head and Neck Squamous Cell Carcinoma

Head/Neck

This phase II trial studies how well radiation therapy works when given with pembrolizumab or cisplatin in treating patients with stages III / IV p16-positive head and neck squamous cell carcinoma. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the bodys immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving pembrolizumab during and after radiation therapy or cisplatin during radiation therapy works better in treating participants with head and neck squamous cell carcinoma.
Head/Neck
II
Gibson, Mike
NCT03383094
VICCHN1966

A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers

Multiple Cancer Types

In this study, adults with non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and squamous-cell carcinoma of the head and neck (SCCHN) will be treated with TAK-676 and pembrolizumab following radiotherapy. The main aims of this study are to check if people are improving after treatment with TAK-676, getting side effects from these combined treatments, and how much TAK-676 people with these cancers can receive without getting unacceptable side effects from it. Participants will receive radiotherapy, then at least 40 hours later will receive pembrolizumab followed by TAK-676 slowly through a vein (infusion). Participants will receive an infusion of pembrolizumab at the same dose every 3 weeks. Different small groups of participants will receive lower to higher doses of TAK-676 on specific days of a 21-day cycle. This study will be happening at sites in North America.
Head/Neck, Lung, Non Small Cell, Phase I
I
Iams, Wade
NCT04879849
VICCHNP20120

A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

Miscellaneous

This is a multi-center, Phase 1 / 2 clinical study for patients with advanced solid tumors. The study consists of 2 treatment arms - a monotherapy arm and a combination arm. The monotherapy arm has 1 part: Dose Escalation (Part A) The combination arm has Dose Escalation (Part B) only.
Miscellaneous
I/II
Berlin, Jordan
NCT03416335
VICCPHI18141

Testing Pembrolizumab with Existing Cancer Therapy in Patients with Evidence of Residual Chronic Myelogenous Leukemia

Leukemia

This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, nilotinib, or bosutinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the bodys immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Dasatinib, imatinib mesylate, nilotinib, and bosutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and dasatinib, imatinib mesylate, nilotinib, or bosutinib may work better in treating patients with chronic myeloid leukemia compared to dasatinib, imatinib mesylate, nilotinib, or bosutinib alone.
Leukemia
II
Mohan, Sanjay
NCT03516279
ECOGHEMEA9171

Study of SRF388 in Patients With Advanced Solid Tumors

Miscellaneous

This is a Phase 1 / 1b, open-label, first-in-human, dose-escalation and expansion study of SRF388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
Miscellaneous
I
Rini, Brian
NCT04374877
VICCMDP2083

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Multiple Cancer Types

To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.
Miscellaneous, Phase I
I
Iams, Wade
NCT04185883
VICCPHI2025

Study of TJ011133 in Participants With Relapsed / Refractory Advanced Solid Tumors and Lymphoma

Multiple Cancer Types

The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.
Miscellaneous, Phase I
I
Berlin, Jordan
NCT03934814
VICCPHI1944

Study of Sacituzumab Govitecan-hziy in Metastatic Urothelial Cancer

Multiple Cancer Types

The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy in participants with metastatic urothelial cancer (mUC).
Bladder, Urologic
II
Davis, Nancy
NCT03547973
VICCURO18120

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: